ACP-211 monotherapy MDD program will report positive interim/topline signal or advance to next-phase dosing within 12 weeks.

ACP-211 is an experimental drug being tested as a standalone treatment for people whose depression hasn't responded to regular antidepressants. Within about three months — so by early November 2026 — the company running the trial is expected to announce either promising early data or that they're moving to the next stage of testing. Companies typically publicize programs only when they're close to good news, so this announcement seems imminent.

Monotherapy framing for inadequate-antidepressant-response MDD is a strategically de-risked positioning. Sponsors only advertise programs near readouts. The unmet need pulls these forward.